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Abstract
Background: An outbreak of Candida auris began globally in 2014 including Pakistan and since then it has
emerged as a nosocomial multi-drug resistant pathogen. The aim of this study was to assess the clinical spectrum
and outcome of patients, from a single center in Pakistan, in whom C. auris was isolated.
Methods: A retrospective study was conducted on 92 patients; ≥16 years with at least one culture positive for C.
auris, at the Aga Khan University Hospital Karachi, Pakistan from Sept 2014-Mar 2017.Demographics, clinical history,
management and outcome were studied. A logistic regression model was used to identify the risk factors for
mortality.
Results: We identified 92 patients with C. auris (193 isolates), of whom 52.2% were males. Mean age was
54.14 ± 20.4 years. Positive cultures were obtained after a median hospital stay of 14 days. Most patients had
a history of surgery (57.6%), antibiotic use (95.6%), ICU stay (44.6%), indwelling lines (88.04%) and isolation
of another multi-resistant organism (52.2%).Most patients were symptomatic (70.7%). Amongst these, 38 had
candidemia while 27 had non-candidemia infections. Sites of infection included central lines (35), urinary
tract (19), peritonitis (4), nosocomial ventriculitis (1), empyema (1), fungal keratitis (1) otitis externa (1) and
surgical site (1). Fluconazole resistance was 100% while 28.5 and 7.9% were Voriconazole and Amphotericin resistant
respectively. Overall crude mortality was 42.4% while 14-day mortality was 31.5%. Both infected and colonized cases
shared similar mortality (46.2% vs 33.3%; p-value = 0.25). Among infected cases mortality was high in candidemia
compared to non-candidemia (60.5% vs 25.9%) in which deaths related to C. auris were 34.2% vs 22.2% respectively.
On multivariate analysis candidemia (AOR 4.2, 95% CI: 1.09–16.49; p-value = 0.037) was associated with greater mortality
with source control being the only protective factor for mortality (AOR 0.22, 95% CI: 0.05–0.92; p-value0.038] while ICU
stay, rapidity of blood culture clearance, DM, malignancy and MDR co-infection had no impact.
Conclusion: Patients with C.auris from a single center in Pakistan have a wide clinical spectrum with line associated
infection being the predominant site of infection. Candidemia leads to high mortality while source control improves
outcome.
Keywords: Candida auris, Candidemia, urinary tract infection, Empyema, Colonization, Mortality
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Background
Candida auris has emerged as an antifungal resistant
yeast causing invasive infections in nosocomial settings.
Improved diagnostics and epidemiological typing techniques are essential to identify and characterize these
strains [1, 2]. It was first reported in Japan in 2009 when
it was isolated from external ear canal [3]. Later in 2011
it was reported for the first time as human pathogen
causing nosocomial fungemia in South Korea and
extremes of age with prior history of surgery was identified as a risk factor [4].C. auris was found to be closely
related to Candida haemulonii and was reported to be
misidentified as C. haemulonii using Vitek 2 YST and
Phoenix (BD). There are numerous other misidentifications using the commercially available diagnostic
methods. API 20CAUX misidentifies it as Rhodotorula
glutinis and C. sake. Vitek 2 (bioMe’rieux) misidentifies
it as C. haemulonii, C. lusitaniae and C. famata while
MicroScan (Beckman Coulter Pasadena, CA) misidentifies this as C. famata, C. lusitaniae, C. guilliermondii, C.
parapsilosis, C. albicans and C. tropicalis [2]. This wrong
identification delayed its diagnosis, a finding later
endorsed by Kathuria S et al in 2015 [5]. It is notable
for its antifungal resistance creating a treatment
dilemma [6–8].
In September 2014, Aga Khan University Hospital, Karachi, Pakistan experienced an outbreak of a yeast which
was initially identified as Saccharomyces cerevisiae [9].
Because of the unusual antifungal susceptibility pattern
of this isolated yeast, these isolates were retested at the
Centers for Disease Control and Prevention (CDC), Atlanta, USA for identification and were eventually identified as C. auris. Simultaneously this pathogen was
reported from India, South Africa and Venezuela and
came to lime light [9]. So far, the available literature has
emphasized on its methods of identification, antifungal
susceptibility and risk factors associated with acquisition.
Studies have shown that factors like extremes of age,
presence of co-morbidities and prior antifungal therapy
are associated with its acquisition while limited data
is available on its disease spectrum and outcomes.
Therefore, in this study, we have reported its clinical
spectrum, outcomes and outcome determining factors
among those with invasive infection. The aim of this
study was to assess the clinical spectrum and outcome of patients, from a single center in Pakistan, in
whom C.auris was isolated.
Methods
We had conducted a retrospective study of 92 hospitalized
patients at the Aga Khan University Hospital (AKUH), a
600-bed tertiary care referral hospital located in Karachi,
Pakistan. All patients with C. auris positive culture from
September 2014–March 2017 were enrolled. Patients aged
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< 16 years or those who did not receive primary treatment
at AKUH were excluded.
Cultures were processed by standard operating procedures in use by the microbiology laboratory as part of
initial clinical work up. Any yeast from a sterile sample
was identified on the basis of germ tube test, appearance
on chromogenic medium BiGGY (Oxoid), cycloheximide
tolerance, microscopic morphology on Cornmeal Agar
(Dalmau method), and profile number on API 20C AUX
(bioMe’rieux). If identification was inconclusive (less
than 90% confidence on API), the antifungal susceptibility
results for Fluconazole and the API number generated
were taken into account. C. auris was presumptively identified by a combination of certain features: resistance to
fluconazole, absence of pseudo hyphae on thin Cornmeal
Tween80 agar, obtaining profile numbers 2,000,130,
2,000,173, 2,102,173, 6,102,173 on API 20C AUX (bioMe’rieux, France). This phenotype had been verified by
D1-D2 sequencing of 28S subunit of rDNA performed on
the first 15 isolates from our institute sent to the Mycotic
Diseases Branch, CDC, Atlanta. There was 100% concordance between the described phenotype and sequencing
results. Antifungal susceptibility was tested using SensititreYeastOne (Trek Diagnostic Systems Ltd., East Grinstead, England) and E-test (bioMe’rieux SA, Marcy
l’Etoile, France). Susceptibilities against fluconazole, voriconazole, and amphotericin B were available for all isolates. For an additional 28 isolates MIC values were also
available against itraconazole, posaconazole, anidulafungin, micafungin and caspofungin. The susceptibilities were
interpreted for Candida species according to CLSI
M27-S3 for triazoles and echinocandins and M27-A3
guidelines for amphotericin B [10, 11]. Briefly, based on
these, the isolate was considered resistant to fluconazole if
MIC was ≥64 μg/ml, voriconazole if MIC was ≥4 μg/ml,
non-susceptible to amphotericin if MIC was > 1 μg/ml,
echinocandins if MIC was > 2 μg/ml. isolates were considered susceptible if MIC to fluconazole was ≤8 μg/ml, voriconazole was ≤1 μg/ml, amphotericin was ≤1 μg/ml, and
echinocandins was ≤2 μg/ml.
Demographic data including age, gender, date of
admission, unit type and a brief history including risk
factors (such as diabetes mellitus, malignancy, prior history of surgery, prior antibiotics or antifungal exposure,
prior ICU stay, indwelling lines and history of isolation
of any other multi-resistant organism), site of infection
and outcomes were collected using data collection
forms. Data was collected by the primary author only.
Patients with C. auris in cultures and associated clinical
sign and symptoms (including but not limited to fever,
site specific symptoms and relevant laboratory parameters such as white blood cells and C-reactive protein)
were labeled as symptomatic/infected. On the other
hand, patients lacking associated clinical signs and
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symptoms with C. auris isolated from non-sterile sites
were considered asymptomatic/colonized. In case of
multiple positive cultures from the same patient the date
of first positive culture was considered as the date of infection/colonization. The site of infection was labeled
using CDC definitions [12]. As candida is excluded from
CDC’s definition for urinary tract infections (UTI), this
was defined as clinical sign and symptoms of a UTI with
positive urine culture in the presence of urinary WBC
and absence of epithelial cells. Asymptomatic candiduria
was defined as presence of C. auris in urine without
clinical sign and symptoms. Standard criteria were used
for the definition of diabetes mellitus and malignancy.
Use of prior antimicrobials was defined as administration of any antibiotic/ antifungal in last 90 days of positive blood culture. Isolation of other multi-drug resistant
(MDR) bacteria before isolating C. auris was defined as
bacteria that were resistant to more than 3 classes of antibiotics, isolated in last 90 days of positive blood culture
for C. auris while co infection with MDR bacteria was
their isolation within 7 days of positive culture for C.
auris. Whenever the given antifungal agent was in
standard-weight based dosage according to site of
infection, and when the isolate was reported as susceptible to it on culture, antifungal therapy was considered
appropriate. This is in accordance with our institute’s
antifungal policy. For all invasive candida cases the first
line empiric antifungal therapy was intravenous Amphotericin B deoxycholate 0.75 mg/kg. Lipid formulations of
amphotericin B were not used. Voriconazole was considered in cases with deranged renal functions when
amphotericin could not be administered. It was given in
a dose of 6 mg/kg 12 hourly on day 1 followed by 4 mg/
kg 12 hourly. Therapeutic drug monitoring for voriconazole was not available. Early appropriate antifungal therapy was the appropriate antifungal therapy given in ≤48
h while late appropriate antifungal therapy was started
48 h after positive culture. Source control was defined as
the removal of inciting agent or focus and entailed the
removal of central line in case of Central Line Associated Blood Stream Infection (CLABSI), Foley’s catheter
in Catheter Associated Urinary Tract Infection (CAUTI),
exploratory laparotomy in peritonitis, drainage of pus
collection and removal of lumbar drain in ventriculitis.
Early source control was the removal of inciting agent in
≤48 h while late source control was when it was achieved
after 48 h of positive culture. Only crude mortality rate
(CMR) was assessed. Microbiological failure was considered in candidemia patients and was defined as failure to
clear blood culture within 4 days while clinical failure
was defined as 14-day mortality or microbiological failure. We considered 14-day mortality as there were large
number of patients who lost to follow-up during the
retrospective chart review. In patients who did not
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survive, cause of death was also assessed by physicians
on clinical and laboratory evidence, and was thought to
be related to C. auris when other causes of death were
excluded and patient had an active C. auris infection at
that time.
We sought ethical approval from University’s Ethics Review Committee (ERC number 4381-MED-ERC-2016).
The committee waived the requirement for informed consent. To preserve confidentiality, we coded each patient
and removed their original identifications.
The collected data were analyzed through Statistical
Package for the Social Sciences (SPSS), version 22.0. For
continuous data, mean and standard deviation/ median
with interquartile range were reported depending on
normality assumption. For categorical data frequency
and percentage were reported. In order to assess association of mortality with independent variables Chi square
test was applied and P value < 0.05 was considered significant. Variables for univariate analysis were based on
known risk factors of mortality for invasive candidiasis
and on the preliminary analysis of our ongoing outbreak
study on C. auris [9, 13]. All statistically significant and
clinically relevant variables of univariate analysis were
included in a multivariate logistic regression analysis to
determine the independent predictive factors of mortality among infective C. auris cases. Results were given as
odds ratios (OR) and 95% confidence intervals (95% CI).

Results
From 2014 to 2017, 193 C. auris strains were isolated
from 92 patients with 16.3% confirmed as C. auris by
D1-D2 sequencing while rest were presumed to be C.
auris. The number of cases with C. auris rose over the
study period from 13 patients in the last quarter 2014 to
46 in 2016 (Fig. 1: Epi-curve of C. auris cases). Table 1
describes the baseline characteristics of the patients. The
median days from admission to positive culture was 14
(IQR-7-130). Most of the patients were older (median
age 55.5 years), were currently or previously admitted to
an Intensive Care Unit/ High Dependency Unit (ICU/
HDU), had indwelling lines (central lines and drains),
and received antibiotics. One in three patients (39.1%)
had also received antifungals in last 90 days of positive
culture. Fifty-two percent had MDR bacteria isolated
from different sites prior to C. auris while 31.5% had a
concomitant MDR bacterial infection.
Antifungal susceptibility was checked in isolates from
63 patients (68.4%) in which fluconazole resistance was
seen in all, voriconazole resistance in 18 (28.6%) and
amphotericin resistance seen in 5 (7.9%) patients. Isolates from 3 patients (4.76%) were resistant to 2 classes
of antifungals (azoles and polyenes) while none were resistant to all classes tested. No echinocandin resistance
was detected.
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Fig. 1 EPI-Curve of Candida Auris cases

Of the 193 C. auris strains, majority were isolated
from blood (75/193) and urine (83/193). Out of 83 urine
specimens 73 were from indwelling catheters, while 10
were mid-stream urine samples. Only 21 patients
(22.8%) isolated C. auris from 2 or more sites.
Of the 92 patients, 65 (70.7%) were infected while 27
(29.3%) were colonized with C. auris. Amongst the infected patients, the most common site of infection was
the bloodstream accounting for 38 (41.3%) cases, most of
which were CLABSIs (35, 38.4%). Of the CLABSI patients,
9 (25.71%) were complicated by seeding to different
organs causing endovascular thrombosis or empyema.
Source of the fungemia could not be identified in 2 patients. Among non-candidemia patients, UTI was the
most commonly seen site infected (19 of 27 patients) with
11 having CAUTI and 8 non-catheter associated UTI.
Of the 65 infected patients, 55 were treated with antifungals, amongst which only 44 patients (67.7%) received
the appropriate antifungal therapy. Early appropriate antifungal therapy was administered to 20 (45.5%) patients.
Amongst the patients who received appropriate antifungal therapy, majority received amphotericin alone (42,
95.5%) while 2 patients were treated with voriconazole
alone. However, 7 patients who initially received amphotericin were later switched to voriconazole. Simultaneous
dual antifungal therapy was not given to any patient.
Out of 38 patients with candidemia, 31 (81.57%) received appropriate antifungal therapy for a mean duration of 18.8 days. Only amphotericin was used to treat
candidemia. Early appropriate antifungals were administered in 16 (51.6%) candidemia patients. However, mortality was higher in those receiving early antifungals (11
of 16, 68.7%) compared to those who received antifungals late (7 of 15; 46.7%). There were 7 patients who did
not receive antifungal therapy, of which 2 cleared their

candidemia with source control alone. Culture clearance
was achieved in 25 out of 27 patients in whom clearance
was checked. However, microbiological failure (i.e. lack
of clearance within 4 days) was seen in 11 patients.
Clearance could not be checked in 10 of the remaining
11 patients due to early mortality.
Amongst the 27 non-candidemia patients, 22 received antifungal, of which 13 were appropriate. In
particular, of the 19 patients with UTI, 10 received
appropriate antifungal therapy for a mean duration of
12 days. In 8 (72.7%) of the 11 patients with CAUTI,
the catheter was removed. Five patients did not receive any antifungal, out of which 2 died within 24 h
of the positive culture. Patients with keratitis received
topical and systemic amphotericin while otitis externa
was managed with clotrimazole ear drops. Compared
to non-candidemia, candidemia patients had a higher
mortality rate (60.5% vs. 25.9%; p-value = 0.006) and
higher 14-day mortality (44.7% vs. 22.2%; p-value =
0.019).
Urine was the most common site of C. auris isolation
in asymptomatic patients (21/27) of whom 17 were catheterized. While the catheter was removed in 10 of these
patients, repeat cultures were sent in 2 patients only,
both of which were negative. Table 2 compares characteristics and outcomes of infected and colonized C. auris
cases. There was no difference in gender, age distribution, location in hospital, co-morbidities, co-infection
with MDR bacteria and probability of dying between the
two.
The median length of hospital stay in all patients was
25 days (IQR 1–163). The CMR was 39 (42.4%) in which
19 deaths (48.7%) were related to C. auris. The 14-day
mortality was 29 (31.5%) and the median days in which
mortality occurred was 7 (IQR 1–69).
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Category

Total n = 92 (100%)

Table 1 Demographics of 92 patients with Candida auris
(Continued)

Male

48 (52.2%)

Category

Age group
16–35 years

20 (21.7%)

36–55 years

26 (28.3%)

56–75 years

30 (32.6%)

76–96 years

16 (17.4%)

Total n = 92 (100%)

Surgical Site Infection

1

Otitis externa

1

Keratitis

1

Colonized cases

27 (29.3%)

Asymptomatic candiduria

21

Central line tip

4

30 (32.6%)

Ear Swab

1

Special care

30 (32.6%)

Oral Swab

1

Ward

27 (29.3%)

Outpatient

5 (5.4%)

Fluconazole

26 (28.3%)

Voriconazole

18 (28.57%)

Malignancy

17 (18.5%)

Amphotericin

5 (7.93%)

Surgery

53 (57.6%)

Mean hospital stay (days)

30.73

Abdominal

12 (13%)

Median hospital stay (days)

25 (1–163)

Cardiothoracic

8 (8.7%)

Mortality

39 (42.4%)

Neurosurgery

14 (15.2%)

C auris death

19 (48.7%)

ENT

9 (9.8%)

14-day mortality

29 (31.5%)

Orthopedics

7 (7.6%)

Mean days in which mortality occurred (days)

12.41

Others

2 (2.17%)

Median days in which mortality occurred (days)

7 (1–69)

ICU stay in last 30 days

41 (44.6%)

Clinical failure

38 (41.3%)

Last ICU stay duration (weeks) ≤ 2 Weeks

31 (75.6%)

Microbiological failure (Candidemia)

11 (40.74%)

HDU stay in last 30 days

62 (67.4%)

Location in hospital
ICU

Diabetes mellitus

Last HDU stay duration (weeks)
≤ 2 Weeks

52 (56.5%)

Indwelling lines

81 (88.04%)

Antibiotics in last 90 days

88 (95.6%)

Antifungals in last 90 days

36 (39.1%)

Fluconazole

19 (20.7%)

Voriconazole

3 (3.3%)

Amphotericin

7 (7.6%)

> 1 Antifungal

7 (7.6%)

Prior antifungal duration (weeks)
≤ 2 Weeks

25 (27.2%)

Isolation of multi-drug resistant bacteria
Prior toC.auris (≤ 90 days)

48 (52.2%)

Coinfection with C.auris

29 (31.5%)

Infected cases

65 (70.7%)

Candidemia

38 (58.5%)

Non-candidemia

27 (41.5%)

UTI

19

Peritonitis

3

Nosocomial ventriculitis

1

Empyema

1

Antifungal resistance (n = 63)
63 (100%)

Table 3 shows details C. auris infective cases and mortality impacting factors. The mean days in which mortality occurred was 5.26 days and 14- day mortality rate
was 94.7%.Compared to the infected survivors, these patients were more likely to be older (56–75 years, AOR
4.5, 95%CI:1.1–18.9) and had candidemia (AOR 4.2,
95%CI: 1.1–16.5). Survivors were also more likely to
have had adequate source control (AOR 0.2, 95%CI:
0.1–0.9).

Discussion
We describe the clinical characteristics and outcomes of
patients in whom C. auris was isolated in a single center
in Pakistan. We found a wide clinical spectrum ranging
from asymptomatic patients to invasive disease including
candidemia, urinary tract infections, empyema and ventriculitis. Most of the infections occurred in critically ill
patients who were admitted for a prolonged period of
time.
The crude in-hospital mortality was 42.4% which is
similar to the mortality rate seen in other studies ranging
from 35.2–60% [9, 14]. A total of 31.5% of the deaths were
related to C. auris infection, majority of whom died within
the first week of acquiring this. This high mortality rate is
in contrast with the UK outbreak reported by Schelenz

Sayeed et al. BMC Infectious Diseases

(2019) 19:384

Page 6 of 8

Table 2 Comparison of C. auris infected patients with C. auris colonizers
Variable

Infection (n = 65)

Colonization (n = 27)

p-value

Male

35 (53.8%)

13 (48.1%)

0.85

16–35

15 (23.1%)

5 (18.5%)

36–55

20 (30.8%)

6 (22.2%)

56–75

21 (32.3%)

9 (33.3%)

76–95

9 (13.8%)

7 (25.9%)

Age group

ICU

23 (35.4%)

7 (25.9%)

HDU

24 (36.9%)

6 (22.2%)

Ward

11 (40.7%)

16 (24.6%)

DM

18 (27.7%)

8 (29.6%)

0.51

0.12

0.85

Malignancy

13 (20%)

5 (18.5%)

0.80

Surgery

39 (60%)

14 (51.9%)

0.61

Co-infection with MDR bacteria

22 (33.8%)

7 (25.9%)

0.45

Appropriate antifungal therapy

44 (67.7%)

0

< 0.001

Source control

40 (61.5%)

7 (25.9%)

< 0.001

Mortality

30 (46.2%)

9 (33.3%)

0.25

14-day mortality

23 (35.4%)

6 (22.2%)

0.45

Clinical failure

24 (64.9%)

6 (22.2%)

< 0.001

Alive

35 (53.8%)

18 (66.7%)

C. auris death

19 (29.2%)

0

Non-auris death

11 (16.9%)

9 (33.3%)

Setal where no deaths were directly attributable to C.
auris [15]. As expected candidemia patients had a higher
mortality, though interestingly, antifungal therapy did not
make a difference in the mortality. Also, paradoxically we
found that mortality was higher in those who received
early antifungal treatment; however this is likely reflective
of the severity of their illness which prompted rapid initiation of amphotericin which is in contrast to other studies
[6, 16]. Moreover, we could not check if this difference
was statistically significant due to the small numbers involved. Mortality was also higher in the older patients,
which has been shown in several other studies [15, 17,
18]. The most important factor impacting outcome was
adequate source control. This is in line with established
treatment guidelines for treating invasive candidiasis [19].
On the other hand, contrary to other studies, diabetes and
malignancy were not associated with mortality in our
study, possibly due to small numbers [14].
We found an annual increase in the number of identified cases at our institute. While patients with C.auris are
managed with barrier precautions, single room isolation is
not possible due to space constraints. Similarly, costs
preclude obtaining environmental and patient surveillance
cultures. As a result, clonal spread of our strains of C.auris
has been documented and highlights the challenges of
infection prevention in resource limited countries [9].

0.005

Despite skepticism regarding the propensity of C. auris
to cause urinary tract infection or empyema as stated by
CDC, we have found that UTI was the second most
common site for symptomatic infection [20]. Moreover,
we describe several unusual infection sites including
wound, peritoneum, otitis externa, keratitis, ventriculitis
and empyema. However, as expected bloodstream infection, in particular CLABSI was the most common infection seen.
The strength of our study is the large number of patients with comprehensive clinical data, giving a better
understanding of the spectrum of disease caused by
C.auris. Moreover, this is the largest series looking at the
gamut of infections caused by the South Asian strain of
C.auris in both ICU and non-ICU patients. However,
our study has several limitations. Firstly, the data was
retrospectively collected leading to potential information
bias. Secondly, and perhaps more importantly, not all of
our C. auris isolates were confirmed by sequencing.
However, the characteristic phenotype we have described
had 100% concordance in the 15 strains in which D1-D2
sequencing was performed. Similarly, we were unable to
perform genetic antifungal resistance testing. However,
of the 15 strains from Pakistan which underwent whole
genome sequencing 2 distinct ERG 11 hotspot mutations
were identified: Y123F and K143R [9].
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Table 3 univariate & multivariate analysis to determine the risk factors for mortality among infective C. auris cases
Category

Died n = 30 (100%)

Survived n = 35 (100%)

Univariate
OR*[95% CI]

Multivariable
P-value

AOR†[95% CI]

P-value

Age group
16–35

5 (16.7%)

10 (28.6%)

1.0

36–55

10 (33.3%)

10 (28.6%)

2.0 [0.5–7.9]

0.32

56–75

13 (43.3%)

08 (22.9%)

3.2 [0.8–13]

0.09

76–96

02 (6.7%)

07 (20%)

0.5 [0.08–3.8]

0.56

ICU

14 (46.7%)

09 (25.7%)

3.4 [0.8–13]

0.07

Special Care

11 (36.7%)

13 (37.1%)

1.86 [0.5–7.0]

0.35

Ward

05 (16.7%)

11 (31.4%)

1.0

0.19

Outpatient

4.5 [1.09–18.9]

0.038

1.2 [0.24–5.8]

0.81

4.2 [1.09–16.49]

0.03

Location in hospital

0

02 (3.1%)

Diabetes Mellitus

11 (36.7%)

07 (20%)

2.3 [0.7–7.0]

0.13

Malignancy

06 (20%)

06 (17.6%)

0.96 [0.20–3.2]

0.95

Candidemia

23 (76.7%)

15 (42.9%)

4.3 [1.4–12]

0.007

Early blood clearance (≤72 h)

02 (18.2%)

5 (35.7%)

1.0

Late blood clearance (> 72 h)

09 (81.8%)

9 (64.3%)

2.5 [0.38–16.42]

0.34

No blood clearance

02 (15.4%)

0 (0)

Appropriate antifungal therapy

23 (76.7%)

21 (60%)

2.2 [0.7–6.4]

0.15

Early antifungal therapy

14 (46.7%)

6 (17.1%)

4.66 [1.2–17.43]

0.02

Late antifungal therapy

09 (30%)

15 (42.9%)

1.2 [0.3–4.09]

0.77

4.1 [0.94–17.9]

0.06

Source control

17 (42.5%)

25 (57.5%)

0.52 [0.18–1.46]

0.2

0.22 [0.05–0.92]

0.038

Early source control

07 (41.2%)

13 (56.5%)

1.0

Late source control

10 (58.8%)

10 (43.5%)

1.5 [0.4–5.3]

0.49

Co infection with multidrug resistant bacteria

13 (43.3%)

09 (25.7%)

2.2 [0.77–6.2]

0.13

2.7 [0.61–12.6]

0.18

0.84 [0.16–4.3]

0.83

*OR, odds ratio
†AOR, adjusted odds ratio

Conclusion
In conclusion, C.auris is associated with a wide variety
of invasive infections and carries a high mortality rate.
Source control is the most effective therapeutic intervention to reduce mortality in these critically ill patients.
Abbreviations
95% CI: 95% Confidence Interval; AAF: Appropriate antifungal; AKUH: Aga
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